Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis.
Ursodeoxycholic acid, 10 to 20 mg/kg per day, was administered for 1 year to 22 patients with cystic fibrosis and chronic cholestasis, resulting in significantly improved liver enzyme values. However, evidence of cholestasis continued, as shown by the pattern of alkaline phosphatase isoenzymes.
Laboratoire de Biochimie, Hôpital Renée Sabran (Hopitaux de Lyon), Giens, Hyères, France.
C
C
Galabert
J C
JC
Montet
D
D
Lengrand
A
A
Lecuire
C
C
Sotta
C
C
Figarella
J P
JP
Chazalette
D015720:5'-Nucleotidase / Q000032:analysis; D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000032:analysis; D000469:Alkaline Phosphatase / Q000032:analysis; D001219:Aspartate Aminotransferases / Q000032:analysis; D001647:Bile Acids and Salts / Q000032:analysis; D001663:Bilirubin / Q000032:analysis; D002648:Child; D002779:Cholestasis / Q000188:drug therapy* / Q000201:enzymology; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000201:enzymology; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*; D005723:gamma-Glutamyltransferase / Q000032:analysis
D001647:Bile Acids and Salts; D014580:Ursodeoxycholic Acid; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D015720:5'-Nucleotidase; D001663:Bilirubin